Neutralization of Tumor Necrosis Factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis

Journal of Infectious Diseases

Volumn 195, Issue 11, 2007, Pages 1643-1650

  Plessner, Hillarie L ^a   Lin, P Ling ^b   Konno, Tadahiko ^c   Louie, James S ^c   Kirschner, Denise ^d   Chan, John ^e   Flynn, JoAnne L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c AMGEN INC   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; DISEASE EXACERBATION; FEMALE; GRANULOMA; INFECTION CONTROL; MOLECULE; MORBIDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

ACUTE DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; COMPLEMENT C3; FEMALE; HUMANS; IMMUNOGLOBULIN G; LUNG; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; TUBERCULOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34249007153     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517519     Document Type: Article

References (34)

1. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545-50.
2. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 2:561-72.
3. Algood HM, Lin PL, Yankura D, Jones A, Chan J, Flynn JL. TNF influences chemokine expression of macrophages in vitro and that of CD11b+ cells in vivo during Mycobacterium tuberculosis infection. J Immunol 2004; 172:6846-57.
4. Bean AG, Roach DR, Briscoe H, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999; 162:3504-11.
5. Mohan VP, Scanga CA, Yu K, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001; 69:1847-55.
6. Keane I, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-104.
7. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002; 2:364-71.
8. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52:3403-12.
9. Cush JJ. Safety overview of new disease-modifying antirheumatic drugs. Rheum Dis Clin North Am 2004; 30:237-55.
10. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261-5. [correction: Clin Infect Dis 2004; 39:54-5]
11. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301:418-26.
12. Serbina NV, Liu CC, Scanga CA, Flynn IL. CD8+ CTL from lungs of Mycobacterium tuberculosis-infected mice express perforin in vivo and lyse infected macrophages. J Immunol 2000; 165:353-63.
13. Scanga CA, Mohan VP, Joseph H, Yu K, Chan J, Flynn JL. Reactivation of latent tuberculosis: variations on the Cornell murine model. Infect Immun 1999; 67:4531-8.
14. Abrams J, Roncarlo MG, Yssel H, Andersson U, Gleich GL, Silver JE. Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev 1992; 127:5-24.
15. Kim HY, Renshaw-Gegg LW, Balciunas AM, Kohno T. Construction and purification of the murine p75- murine IgGI fusion protein. J Invest Dermatol Symp Proc 2007; 12:48-9.
16. Hu YL, Kim H, Kohno T, Khare SD. Pharmacodynamic effects of the murine p75-Fc fusion protein in mice. J Invest Dermatol Symp Proc 2007; 12:50-1.
17. Sud D, Bigbee C, Flynn JL, Kirschner DE. Contribution of CD8+ T cells to control of Mycobacterium tuberculosis infection. J Immunol 2006; 176:4296-314.
18. Scott HM, Flynn JL. Mycobacterium tuberculosis in chemokine receptor 2-deficient mice: influence of dose on disease progression. Infect Immun 2002; 70:5946-54.
19. Eskandari MK, Nguyen DT, Kunkel SL, Remick DG. WEHI 164 subclone 13 assay for TNF: sensitivity, specificity and reliability. Immunol Invest 1990; 19:69-79.
20. Catrina AI, Trollmo C, af Klint E, et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 2005; 52:61-72.
21. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124:1774-85.
22. Smeets TJ, Kraan MC, van Loon ME, Tak PP. Tumor necrosis factor α blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003; 48:2155-62.
23. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121:1145-57.
24. Emile JF, Patey N, Altare F, et al. Correlation of granuloma structure with clinical outcome defines two types of idiopathic disseminated BCG infection. J Pathol 1997; 181:25-30.
25. Flynn JL. Lessons from experimental Mycobacterium tuberculosis infections. Microbes Infect 2006; 8:1179-88.
26. Mpofu S, Fatima F, Moots RJ. Anti-TNF-α therapies: they are all the same (aren't they?). Rheumatology (Oxford) 2005;44:271-3.
27. Saunders BM, Briscoe H, Britton WJ. T cell-derived tumour necrosis factor is essential, but not sufficient, for protection against Mycobacterium tuberculosis infection. Clin Exp Immunol 2004; 137:279-87.
28. Eissner G, Kohlhuber F, Grell M, et al. Critical involvement of transmembrane tumor necrosis factor-α in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin. Blood 1995; 86:4184-93.
29. Keane J, Balcewicz-Sablinska MK, Remold HG, et al. Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis. Infect Immun 1997; 65:298-304.
30. Anderson CF, Gerber JS, Mosser DM. Modulating macrophage function with IgG immune complexes. J Endotoxin Res 2002; 8:477-81.
31. Turner J, Gonzalez-Juarrero M, Ellis DL, et al. In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. J Immunol 2002; 169:6343-51.
32. Co DO, Hogan LH, Il-Kim S, Sandor M. T cell contributions to the different phases of granuloma formation. Immunol Lett 2004; 92:135-42.
33. Raju B, Hoshino Y, Kuwabara K, et al. Aerosolized gamma interferon (IFN-gamma) induces expression of the genes encoding the IFN-gamma-inducible 10-kilodalton protein but not inducible nitric oxide synthase in the lung during tuberculosis. Infect Immun 2004; 72:1275-83.
34. Tufariello JM, Chan J, Flynn JL. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis 2003;3:578-90.